Standing Orders for Administering Pneumococcal Polysaccharide (PPSV23) Vaccine to Children and Adolescents

**Purpose:** To reduce morbidity and mortality from pneumococcal disease by vaccinating all pediatric patients who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate pediatric patients who meet the criteria below.

**Procedure:**

1. Identify pediatric patients in need of vaccination with pneumococcal polysaccharide vaccine (PPSV23) based on the following criteria:
   - age 2-18 years of age with no or unknown history of prior receipt of PPSV23 and any of the following underlying conditions (see table below):
     - chronic cardiovascular disease (particularly cyanotic congenital heart disease and cardiac failure).
     - chronic pulmonary disease (asthma is excluded unless treated with high-dose corticosteroid therapy).
     - diabetes mellitus
     - chronic liver disease (cirrhosis), or alcoholism (patients 6 - 18 years of age only).
     - candidate for or recipient of cochlear implant; cerebrospinal fluid leak.
     - sickle cell disease, hemoglobinopathies, anatomic or functional asplenia (splenectomy, splenic dysfunction).
     - immunocompromising condition (e.g., congenital immunodeficiency, HIV infection, hematologic cancers, malignant neoplasms).
     - immunosuppressive therapy (e.g., antineoplastic agents, antimetabolites, biologics, high-dose corticosteroids, radiation therapy).
     - chronic renal failure or nephrotic syndrome; organ or bone marrow transplantation.
     - environments or settings with increased risk (e.g., long-term care facility).

2. Screen all patients for contraindications and precautions to PPSV23 vaccine:

   **Contraindications:**
   - a history of a severe allergic reaction (e.g. anaphylaxis) to any prior dose of PPSV23 vaccine or any of its components.
   - for a list of vaccine components, please see:
     - the [manufacturer’s package insert](#)
     - the [CDC Vaccine Excipient & Media Summary](#)

   **Precautions:**
   - moderate or severe acute illness, with or without fever.
   - for questions or concerns, consider consulting the DHA Immunization Healthcare Division at 877-438-8222, Option 1.

Reviewed by DHA-IHD 7/29/2019
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). Staff must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (or parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Administer vaccine as follows:
   • 0.5mL via the intramuscular (IM) or subcutaneous (SC) route. Choose a needle length appropriate to the route and patient’s age or body mass. See “Dose, Route, Needle Size” in this publication or at http://www.immunize.org/catg.d/p3085.pdf

5. Documentation:
   • document all immunizations administered in the patient’s electronic health record. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov. Additional information about VAERS is available by telephone at 800-822-7967.

8. This policy and procedure shall remain in effect for all patients of the ___________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  __________________________
Medical Director’s Signature                  Date
Recommended Schedule for Administering Pneumococcal Polysaccharide Vaccine (PPSV23)

<table>
<thead>
<tr>
<th>Underlying Condition</th>
<th>Primary PPSV23 Series</th>
<th>PPSV23 Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td>• chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure)</td>
<td>1 dose 28 weeks after the last dose of PCV13</td>
<td>Not recommended</td>
</tr>
<tr>
<td>• chronic lung disease (asthma excluded unless treated with high-dose corticosteroids)</td>
<td>1 dose 28 weeks after the last dose of PCV13</td>
<td>1 dose 25 years after the first dose of PPSV23</td>
</tr>
<tr>
<td>• diabetes mellitus; cerebrospinal fluid leak; cochlear implant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• alcoholism, chronic liver disease*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• sickle cell disease and other hemoglobinopathies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• congenital or acquired asplenia, or splenic dysfunction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• HIV infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• chronic renal failure, nephrotic syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• diseases commonly treated with immunosuppressive drugs or radiation therapy (e.g., malignant neoplasms, leukemias, lymphomas, and Hodgkin’s disease; solid organ transplantation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• congenital immunodeficiency (including B- [humoral] or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, or C4 deficiency; and phagocytic disorders [excluding chronic granulomatous disease])</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Patients 6 - 18 years of age ONLY
Adapted from Immunization Action Coalition: www.immunize.org/catg.d/p2016.pdf · Item #P2016 (10/18)

---

Pneumococcal Vaccine Timing For Children: PPSV23

**Ages 2-18 Years With Underlying Condition(s)**

- DO NOT administer PCV13 and PPSV23 at the same visit.
- Complete all recommended doses of PCV13 before giving PPSV23.
- Prior doses count towards doses recommended below and do not need to be repeated.
- If PPSV23 given previously – for group B, wait at least five years before giving a second dose of PPSV23.
- No more than two doses of PPSV23 recommended before age 65 years.

**A. Chronic conditions:**
- Diabetes
- **Heart Disease** (particularly failure or cyanotic disease)
- **Lung disease** (excluding asthma, unless treated with high-dose corticosteroids - see below)
- CSF leaks or cochlear implants

**B. Immunocompromised** (including HIV or immunosuppressive treatments)
- **Hemoglobinopathy** (including sickle cell disease)
- Asplenia
- Chronic renal failure or nephrotic syndrome

For further details, see: www.cdc.gov/vaccines/hcp/aci-pga/vacc-specific/pneumo.html

Graphic adapted from the California Department of Public Health, Immunization Branch: www.EZiZ.org

Reviewed by DHA-IHD 7/29/2019